Comparative Pharmacology
Head-to-head clinical analysis: FELDENE versus PONSTEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FELDENE versus PONSTEL.
FELDENE vs PONSTEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
20 mg orally once daily, or 10 mg orally twice daily. Maximum daily dose: 20 mg.
250 mg orally every 6 hours as needed, not to exceed 1 g per day, for no longer than 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 50 hours (range 30-86 hours), allowing once-daily dosing. The long half-life results from enterohepatic recirculation.
2-4 hours (terminal elimination half-life); clinical context: duration of analgesia 4-6 hours; accumulates with renal impairment
Approximately 60-70% of a dose is excreted in urine as unchanged drug and metabolites, with about 30-40% eliminated in feces via biliary secretion.
Primarily renal (70-80% as glucuronide conjugates and unchanged drug); biliary/fecal (20-30%)
Category C
Category C
Nonsteroidal Anti-Inflammatory Drug
Nonsteroidal Anti-Inflammatory Drug